Clinical Trial

Colonoscopy and Antiplatelet Therapy Trial

Study acronym: CAPTT
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 25, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Patients on dual antiplatelet therapy )aspirin plus a P2Y12 inhibitor \[clopidogrel, prasugrel, or ticagrelor\]) undergoing screening or surveilance colonoscopy are at increased risk for bleeding from the procedure. Patients are ussually asked to stop the P2Y12 inhibitor for the procedure. Currently, recommendation is that patients only on a P2Y12 inhibitor be changes to aspirin for the procedure. This pilot study will evaluate if there is a large difference in bleeding between patients only taking aspirin compared with patients only taking a P2Y12 inhibitor. Patinets who participate will randomly be randomly asked to stop either aspirin or the P2Y12 inhibitor 1 week before the procedure. Periprocedural bleeding and bleeding after the procedure for iup to 30 days.
Trial Details
NCT Number NCT06613191
Lead Sponsor Ochsner Health System
Conditions Coronary Arterial Disease (CAD), Peripheral Vascular Disease
Enrollment 100 participants
Start Date 2024-10-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-25